



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

13 March 2020
EMA/COMP/94360/2020
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Orphan Medicinal Products (COMP)

Draft agenda for the meeting on 17-19 March 2020

Chair: Violeta Stoyanova-Beninska – Vice-Chair: Armando Magrelli

17 March 2020, 09:00-19:30, room 2A

18 March 2020, 08:30-19:30, room 2A

19 March 2020, 08:30-13:00, room 2A

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for COMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members and experts.....	5
1.2.	Adoption of agenda.....	5
1.3.	Adoption of the minutes	5
2.	Applications for orphan medicinal product designation	5
2.1.	For opinion	5
2.1.1.	- EMA/OD/0000019167	5
2.1.2.	- EMA/OD/0000020629	5
2.1.3.	- EMA/OD/0000021732	5
2.1.4.	- EMA/OD/0000022351	5
2.1.5.	- EMA/OD/0000022586	5
2.1.6.	- EMA/OD/0000022633	6
2.1.7.	- EMA/OD/0000022802	6
2.1.8.	- EMA/OD/0000022808	6
2.1.9.	- EMA/OD/0000022918	6
2.2.	For discussion / preparation for an opinion.....	6
2.2.1.	- EMA/OD/0000009482	6
2.2.2.	- EMA/OD/0000018294	6
2.2.3.	- EMA/OD/0000019446	6
2.2.4.	- EMA/OD/0000020387	6
2.2.5.	- EMA/OD/0000020940	6
2.2.6.	- EMA/OD/0000021576	7
2.2.7.	- EMA/OD/0000022133	7
2.2.8.	- EMA/OD/0000022335	7
2.2.9.	- EMA/OD/0000023090	7
2.2.10.	- EMA/OD/0000023410	7
2.2.11.	- EMA/OD/0000023461	7
2.2.12.	- EMA/OD/0000023599	7
2.2.13.	- EMA/OD/0000023893	7
2.2.14.	- EMA/OD/0000023973	7
2.2.15.	- EMA/OD/0000023993	8
2.2.16.	- EMA/OD/0000023994	8
2.3.	Revision of the COMP opinions	8
2.3.1.	- EMA/OD/0000020769	8
2.3.2.	- EMA/OD/0000020844	8
2.4.	Amendment of existing orphan designations.....	8

2.5.	Appeal	8
2.6.	Nominations	8
2.6.1.	New applications for orphan medicinal product designation - Appointment of COMP rapporteurs.....	8
2.7.	Evaluation on-going.....	8
3. Requests for protocol assistance with significant benefit question 9		
3.1.	Ongoing procedures	9
3.1.1.	-.....	9
3.1.2.	-.....	9
3.2.	Finalised letters.....	9
3.3.	New requests.....	9
3.3.1.	-.....	9
3.3.2.	-.....	9
3.3.3.	-.....	9
3.3.4.	-.....	9
3.3.5.	-.....	9
4. Review of orphan designation for orphan medicinal products at time of initial marketing authorisation 10		
4.1.	Orphan designated products for which CHMP opinions have been adopted	10
4.1.1.	OFEV - nintedanib – EMEA/H/C/003821/II/0026, EMA/OD/186/12, EU/3/16/1724, EMA/OD/0000005310	10
4.2.	Orphan designated products for discussion prior to adoption of CHMP opinion	10
4.2.1.	- pexidartinib – EMEA/H/C/004832, EMA/OD/279/14, EU/3/15/1457, EMA/OD/0000021360	10
4.2.2.	- bulevirtide – EMEA/H/C/004854, EMA/OD/329/14, EU/3/15/1500, EMA/OD/0000018086	10
4.2.3.	- onasemnogene abeparvovec – EMEA/H/C/004750, EMA/OD/028/15, EU/3/15/1509, EMA/OD/0000003028	10
4.2.4.	- pretomanid – EMEA/H/C/005167, EMA/OD/074/07, EU/3/07/513, EMA/OD/0000021750	10
4.3.	Appeal	10
4.4.	On-going procedures	11
4.5.	Orphan Maintenance Reports.....	11
5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension 11		
5.1.	After adoption of CHMP opinion.....	11
5.2.	Prior to adoption of CHMP opinion.....	11
5.2.1.	Adcetris - brentuximab vedotin - Type II variation – EMEA/H/C/002455/II/0070 - EMEA/OD/072/08, EU/3/08/595, EMA/OD/0000007448.....	11
5.2.2.	Kyprolis - carfilzomib - Type II variation - EMEA/H/C/003790/II/0045, EMA/OD/120/07, EU/3/08/548, EMA/OD/0000030043	11

5.2.3.	Zejula - niraparib - Type II variation - EMEA/H/C/004249/II/0019 - EMA/OD/015/10, EU/3/10/760, EMA/OD/0000031233	11
5.2.4.	Imbruvica – ibrutinib - Type II variation - EMEA/H/C/003791/II/0059, EMA/OD/156/11, EU/3/12/984, EMA/OD/0000026247	11
5.3.	Appeal	12
5.4.	On-going procedures	12
6.	Application of Article 8(2) of the Orphan Regulation	12
7.	Organisational, regulatory and methodological matters	12
7.1.	Mandate and organisation of the COMP	12
7.1.1.	Strategic Review & Learning meeting – COMP, 12-14 February 2020, Zagreb, Croatia.....	12
7.1.2.	Protocol Assistance Working Group (PAWG)	12
7.2.	Coordination with EMA Scientific Committees or CMDh-v	12
7.2.1.	Recommendation on eligibility to PRIME – report from CHMP	12
7.2.2.	COMP-CAT Working Group	12
7.2.3.	COMP members nominated on EMA's recommendation	13
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	13
7.3.1.	Working Party with Patients’ and Consumers’ Organisations (PCWP)	13
7.3.2.	Working Party with Healthcare Professionals’ Organisations (HCPWP).....	13
7.4.	Cooperation within the EU regulatory network.....	13
7.4.1.	European Commission.....	13
7.5.	Cooperation with International Regulators.....	13
7.5.1.	Food and Drug Administration (FDA).....	13
7.5.2.	Japanese Pharmaceuticals and Medical Devices Agency (PMDA).....	13
7.5.3.	Therapeutic Goods Administration (TGA), Australia	13
7.5.4.	Health Canada.....	13
7.6.	Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee.....	13
7.7.	COMP work plan	14
7.8.	Planning and reporting	14
7.8.1.	List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2020	14
7.8.2.	Overview of orphan marketing authorisations/applications.....	14
8.	Any other business	14
9.	Explanatory notes	14

1. Introduction

1.1. Welcome and declarations of interest of members and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the COMP plenary session to be held 17-19 March 2020. See March 2020 COMP minutes (to be published post April 2020 COMP meeting).

1.2. Adoption of agenda

COMP agenda for 17-19 March 2020.

1.3. Adoption of the minutes

COMP minutes for 18-20 February.

2. Applications for orphan medicinal product designation

2.1. For opinion

2.1.1. - [EMA/OD/0000019167](#)

Treatment of ovarian cancer

Action: For adoption, Oral explanation to be held on 17 March 2020 at 17:30

2.1.2. - [EMA/OD/0000020629](#)

Treatment of small cell lung cancer (SCLC)

Action: For adoption, Oral explanation to be held on 17 March 2020 at 09:30

2.1.3. - [EMA/OD/0000021732](#)

Treatment of hepatocellular carcinoma

Action: For adoption, Oral explanation to be held on 18 March 2020 at 14:00

2.1.4. - [EMA/OD/0000022351](#)

Prevention of graft versus host disease

Action: For adoption, Oral explanation to be held on 17 March 2020 at 15:00

2.1.5. - [EMA/OD/0000022586](#)

Treatment of von Hippel-Lindau disease

Action: For adoption, Oral explanation to be held on 18 March 2020 at 15:30

2.1.6. - [EMA/OD/0000022633](#)

Prevention of retinopathy of prematurity

Action: For adoption, Oral explanation to be held on 18 March 2020 at 17:00

2.1.7. - [EMA/OD/0000022802](#)

Treatment of acute myeloid leukaemia

Action: For adoption, Oral explanation to be held on 17 March 2020 at 11:00

2.1.8. - [EMA/OD/0000022808](#)

Treatment of intrahepatic cholestasis of pregnancy

Action: For adoption, Oral explanation to be held on 17 March 2020 at 16:30

2.1.9. - [EMA/OD/0000022918](#)

Treatment of myasthenia gravis

Action: For adoption, Oral explanation to be held on 19 March 2020 at 09:00

2.2. For discussion / preparation for an opinion

2.2.1. - [EMA/OD/0000009482](#)

Treatment of retinal detachment

Action: For discussion/adoption

2.2.2. - [EMA/OD/0000018294](#)

Treatment of acute myeloid leukaemia

Action: For discussion/adoption

2.2.3. - [EMA/OD/0000019446](#)

Treatment of Cushing's Disease

Action: For discussion/adoption

2.2.4. - [EMA/OD/0000020387](#)

Treatment of progressive familial intrahepatic cholestasis (PFIC)

Action: For discussion/adoption

2.2.5. - [EMA/OD/0000020940](#)

Treatment of multiple myeloma

Action: For discussion/adoption

[2.2.6. - EMA/OD/0000021576](#)

Diagnosis of AL Amyloidosis

Action: For discussion/adoption

[2.2.7. - EMA/OD/0000022133](#)

Treatment of pyruvate kinase deficiency

Action: For discussion/adoption

[2.2.8. - EMA/OD/0000022335](#)

Treatment of pericarditis

Action: For discussion/adoption

[2.2.9. - EMA/OD/0000023090](#)

Treatment of marginal zone lymphoma

Action: For discussion/adoption

[2.2.10. - EMA/OD/0000023410](#)

Treatment of multiple myeloma

Action: For discussion/adoption

[2.2.11. - EMA/OD/0000023461](#)

Treatment of primary sclerosing cholangitis

Action: For discussion/adoption

[2.2.12. - EMA/OD/0000023599](#)

Prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)

Action: For discussion/adoption

[2.2.13. - EMA/OD/0000023893](#)

Treatment of haemophilia A

Action: For discussion/adoption

[2.2.14. - EMA/OD/0000023973](#)

Treatment of insulin autoimmune syndrome

Action: For discussion/adoption

2.2.15. - EMA/OD/0000023993

Treatment of insulinoma

Action: For discussion/adoption

2.2.16. - EMA/OD/0000023994

Treatment of esophageal squamous cell carcinoma

Action: For discussion/adoption

2.3. Revision of the COMP opinions

2.3.1. - EMA/OD/0000020769

Treatment of intracerebral haemorrhage

Action: For adoption

2.3.2. - EMA/OD/0000020844

Treatment of eumycetoma

Action: For adoption

2.4. Amendment of existing orphan designations

None

2.5. Appeal

None

2.6. Nominations

2.6.1. New applications for orphan medicinal product designation - Appointment of COMP rapporteurs

Action: For adoption

Document tabled:

OMPD applications - appointment of rapporteurs at the 17-19 March 2020 COMP meeting

2.7. Evaluation on-going

Fifteen applications for orphan designation will not be discussed as evaluation is ongoing.

Action: For information

Notes: See 7.8.1. table

3. Requests for protocol assistance with significant benefit question

3.1. Ongoing procedures

3.1.1. -

Prevention of ischaemia reperfusion injury associated with solid organ transplantation

Action: For adoption

3.1.2. -

Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)

Action: For adoption

3.2. Finalised letters

None

3.3. New requests

3.3.1. -

Treatment of Niemann-Pick disease type C

Action: For information

3.3.2. -

Treatment of mucopolysaccharidosis type II (Hunter syndrome)

Action: For information

3.3.3. -

Treatment of hepatocellular carcinoma

Action: For information

3.3.4. -

Treatment of diffuse large B-cell lymphoma

Action: For information

3.3.5. -

Treatment of pseudomyxoma peritonei (mucinous peritoneal tumour)

Action: For information

4. Review of orphan designation for orphan medicinal products at time of initial marketing authorisation

4.1. Orphan designated products for which CHMP opinions have been adopted

- 4.1.1. OFEV - nintedanib – EMEA/H/C/003821/II/0026, EMA/OD/186/12, EU/3/16/1724, EMA/OD/0000005310
-

MYR GmbH; Treatment of systemic sclerosis

CHMP rapporteur: Peter Kiely; CHMP co-rapporteur: Ewa Balkowiec Iskra

Action: For adoption

4.2. Orphan designated products for discussion prior to adoption of CHMP opinion

- 4.2.1. - pexidartinib – EMEA/H/C/004832, EMA/OD/279/14, EU/3/15/1457, EMA/OD/0000021360
-

Daiichi Sankyo Europe GmbH; Treatment of tenosynovial giant cell tumour, localised and diffuse type

Action: For adoption, Oral explanation to be held on 18 March 2020 at 12:00

- 4.2.2. - bulevirtide – EMEA/H/C/004854, EMA/OD/329/14, EU/3/15/1500, EMA/OD/0000018086
-

Accelerated assessment

MYR GmbH; Treatment of hepatitis delta virus infection

Action: For adoption, Oral explanation to be held on 18 March 2020 at 09:00

- 4.2.3. - onasemnogene abeparvovec – EMEA/H/C/004750, EMA/OD/028/15, EU/3/15/1509, EMA/OD/0000003028
-

AveXis Netherlands B.V.; Treatment of spinal muscular atrophy

Action: For information

- 4.2.4. - pretomanid – EMEA/H/C/005167, EMA/OD/074/07, EU/3/07/513, EMA/OD/0000021750
-

FGK Representative Service GmbH; Treatment of tuberculosis

Action: For discussion

4.3. Appeal

None

4.4. On-going procedures

Action: For information

Document(s) tabled:

Review of orphan designation for OMP for MA - On-going procedures

4.5. Orphan Maintenance Reports

None

5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension

5.1. After adoption of CHMP opinion

None

5.2. Prior to adoption of CHMP opinion

5.2.1. Adcetris - brentuximab vedotin - Type II variation – EMEA/H/C/002455/II/0070 - EMEA/OD/072/08, EU/3/08/595, EMA/OD/0000007448

Takeda Pharma A/S; Treatment of peripheral T-cell lymphoma

CHMP rapporteur: Paula Boudewina van Hennik

Action: For discussion

5.2.2. Kyprolis - carfilzomib - Type II variation - EMEA/H/C/003790/II/0045, EMA/OD/120/07, EU/3/08/548, EMA/OD/0000030043

Amgen Europe B.V.; Treatment of multiple myeloma

CHMP rapporteur: Jorge Camarero

Action: For discussion

5.2.3. Zejula - niraparib - Type II variation - EMEA/H/C/004249/II/0019 - EMA/OD/015/10, EU/3/10/760, EMA/OD/0000031233

GlaxoSmithKline (Ireland) Limited; Treatment of ovarian cancer

CHMP rapporteur: Bjorg Bolstad;

Action: For discussion

5.2.4. Imbruvica – ibrutinib - Type II variation - EMEA/H/C/003791/II/0059, EMA/OD/156/11, EU/3/12/984, EMA/OD/0000026247

Janssen-Cilag International NV; Treatment of chronic lymphocytic leukaemia

CHMP rapporteur: Filip Josephson

Action: For discussion

5.3. Appeal

None

5.4. On-going procedures

Action: For information

Document(s) tabled:

Review of orphan designation for OMP for MA extension - On-going procedures

6. Application of Article 8(2) of the Orphan Regulation

None

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the COMP

7.1.1. Strategic Review & Learning meeting – COMP, 12-14 February 2020, Zagreb, Croatia

Report from the meeting

Action: For information

7.1.2. Protocol Assistance Working Group (PAWG)

Proposed meeting time on 17 March 2020 at 18:30 in room 2D.

Document tabled:

PAWG draft agenda for 17 March 2020 meeting

7.2. Coordination with EMA Scientific Committees or CMDh-v

7.2.1. Recommendation on eligibility to PRIME – report from CHMP

Action: For information

Document(s) tabled:

PRIME eligibility requests - list of adopted outcomes February 2020

7.2.2. COMP-CAT Working Group

Proposed meeting time on 18 March 2020 at 18:30 in room 1B.

Action: For discussion

Document(s) tabled:

Agenda and related documents

7.2.3. COMP members nominated on EMA's recommendation

Action: For information

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Working Party with Patients' and Consumers' Organisations (PCWP)

None

7.3.2. Working Party with Healthcare Professionals' Organisations (HCPWP)

None

7.4. Cooperation within the EU regulatory network

7.4.1. European Commission

None

7.5. Cooperation with International Regulators

7.5.1. Food and Drug Administration (FDA)

Action: For information

Notes: Monthly teleconference

7.5.2. Japanese Pharmaceuticals and Medical Devices Agency (PMDA)

Action: For information

Notes: Ad hoc basis meeting

7.5.3. Therapeutic Goods Administration (TGA), Australia

Action: For information

Notes: Ad hoc basis meeting

7.5.4. Health Canada

Action: For information

Notes: Ad hoc basis meeting

7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee

None

7.7. COMP work plan

None

7.8. Planning and reporting

7.8.1. List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2020

Action: For information

7.8.2. Overview of orphan marketing authorisations/applications

Action: For information

8. Any other business

None

9. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the COMP agenda and should be read in conjunction with the agenda or the minutes.

Abbreviations / Acronyms

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

EC: European Commission

OD: Orphan Designation

PA: Protocol Assistance

PDCO: Paediatric Committee

PRAC: Pharmacovigilance and Risk Assessment Committee

SA: Scientific Advice

SAWP: Scientific Advice Working Party

Orphan Designation (*section 2 Applications for orphan medicinal product designation*)

The orphan designation is the appellation given to certain medicinal products under development that are intended to diagnose, prevent or treat rare conditions when they meet a pre-defined set of criteria foreseen in the legislation. Medicinal products which get the orphan status benefit from several incentives (fee reductions for regulatory procedures (including protocol assistance), national incentives for research and development, 10-year market exclusivity) aiming at stimulating the development and availability of treatments for patients suffering from rare diseases.

Orphan Designations are granted by Decisions of the European Commission based on opinions from the COMP. Orphan designated medicinal products are entered in the Community Register of Orphan Medicinal Products.

Protocol Assistance (*section 3 Requests for protocol assistance with significant benefit question*)

The protocol assistance is the help provided by the Agency to the sponsor of an orphan medicinal product, on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product in view of the submission of an application for marketing authorisation.

Sponsor

Any legal or physical person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product.

Maintenance of Orphan Designation (*section 4 Review of orphan designation for orphan medicinal products for marketing authorisation*).

At the time of marketing authorisation, the COMP will check if all criteria for orphan designation are still met. The designated orphan medicinal product should be removed from the Community Register of Orphan Medicinal Products if it is established that the criteria laid down in the legislation are no longer met.

More detailed information on the above terms can be found on the EMA website:

www.ema.europa.eu/